麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Sep 14 2023

Full Issue

Viewpoints: One Opioid Treatment Not As Safe As Previously Thought; Doctors Are Not OK

Editorial writers delve into a opioid misuse treatment, doctors' mental health, "medical assistance in dying," and more.

Vivitrol, a monthly injection of long-acting naltrexone, is the opioid treatment preferred by the criminal prosecution system, including jails, prisons, probation officers and drug courts. This is in part because it is not a controlled substance, unlike the other two medications, and in part because the drug鈥檚 maker, Alkermes, has heavily promoted it to those markets by claiming it is as safe as the other medications and easier to administer since it doesn鈥檛 have to be taken daily. (Maia Szalavitz, 9/13)

In the realm of healing, physicians are the unsung heroes. Yet, behind the white coats and stethoscopes, there is a pressing concern that demands the greater society鈥檚 attention: the wellness of our healers themselves. (Ed Cappaelli, 9/13)

Rebranded 鈥渕edical assistance in dying" 鈥 鈥淢AiD鈥 鈥 euthanasia in Canada has gone from illegal to commonplace in less than a decade. Since 2016, doctors have administered some 30,000 lethal injections 鈥 one-third of them in 2021 alone 鈥 at the request of eligible patients. The 2021 number, 10,029, was up 34.7 percent from 7,446 in 2020, and represented 3.3 percent of all deaths. (Charles Lane, 9/13)

The rapid rise of artificial intelligence creates as much risk to the delivery of healthcare as it does opportunity. One of the most significant risks is that if we don鈥檛 develop and deploy AI tools carefully, they could widen existing disparities in care rather than enhance the industry鈥檚 efforts to improve health equity. (Dr. Rebecca Grochow Mishuris, 9/12)

Currently, more than 10,000 Texans are waiting for a lifesaving organ transplant, with people of color representing nearly 70% of that need, according to Donate Life Texas. Yet, data shows these same communities are less likely to register as donors. As a Black woman in Texas, this isn鈥檛 just a data point, it鈥檚 my life. (Nichole Jefferson, 9/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优